Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Lenalidomide for Relapsed/Refractory AML
NCT01743859Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Dec 2012
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, lenalidomide in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Colorado Denver. Started Dec 2012; status: completed.
02
Drugs
azacitidinelenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01743859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01743859.